In February 2006, Croatian pharmaceutical company PLIVA announced that it is to sell its Zagreb R&D unit to GlaxoSmithKline so that it can concentrate on the generics side of its business...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: PharmaDeals Ltd